<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gorijala P</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><funding>NICHD NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>NIBIB NIH HHS</funding><funding>NIA NIH HHS</funding><funding>National Institutes of Health</funding><funding>Alzheimer&amp;apos;s Association</funding><funding>Chan Zuckerberg Initiative</funding><funding>National Institute on Aging</funding><funding>Deutsches Zentrum für Neurodegenerative Erkrankungen</funding><funding>Japan Agency for Medical Research and Development</funding><funding>Alzheimer&amp;apos;s Disease Neuroimaging Initiative</funding><funding>Korea Health Industry Development Institute</funding><funding>Alzheimer's Association</funding><funding>NIH HHS</funding><funding>National Institute of Biomedical Imaging and Bioengineering</funding><funding>Michael J. Fox Foundation for Parkinson&amp;apos;s Research</funding><pagination>1038-1049</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10916941</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(2)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>This study aimed to investigate the influence of the overall Alzheimer's disease (AD) genetic architecture on Down syndrome (DS) status, cognitive measures, and cerebrospinal fluid (CSF) biomarkers.&lt;h4>Methods&lt;/h4>AD polygenic risk scores (PRS) were tested for association with DS-related traits.&lt;h4>Results&lt;/h4>The AD risk PRS was associated with disease status in several cohorts of sporadic late- and early-onset and familial late-onset AD, but not in familial early-onset AD or DS. On the other hand, lower DS Mental Status Examination memory scores were associated with higher PRS, independent of intellectual disability and APOE (PRS including APOE, PRS&lt;sub>APOE&lt;/sub> , p = 2.84 × 10&lt;sup>-4&lt;/sup> ; PRS excluding APOE, PRS&lt;sub>nonAPOE&lt;/sub> , p = 1.60 × 10&lt;sup>-2&lt;/sup> ). PRS&lt;sub>APOE&lt;/sub> exhibited significant associations with Aβ42, tTau, pTau, and Aβ42/40 ratio in DS.&lt;h4>Discussion&lt;/h4>These data indicate that the AD genetic architecture influences cognitive and CSF phenotypes in DS adults, supporting common pathways that influence memory decline in both traits.&lt;h4>Highlights&lt;/h4>Examination of the polygenic risk of AD in DS presented here is the first of its kind. AD PRS influences memory aspects in DS individuals, independently of APOE genotype. These results point to an overlap between the genes and pathways that leads to AD and those that influence dementia and memory decline in the DS population. APOE ε4 is linked to DS cognitive decline, expanding cognitive insights in adults.</pubmed_abstract><journal>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</journal><pubmed_title>Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.</pubmed_title><pmcid>PMC10916941</pmcid><funding_grant_id>U01AG058922</funding_grant_id><funding_grant_id>W81XWH‐12‐2‐0012</funding_grant_id><funding_grant_id>RF1 AG044546</funding_grant_id><funding_grant_id>RF1AG058501</funding_grant_id><funding_grant_id>UL1 TR002373</funding_grant_id><funding_grant_id>R01AG064877</funding_grant_id><funding_grant_id>RF1 AG071706</funding_grant_id><funding_grant_id>U54 HD087011</funding_grant_id><funding_grant_id>SG‐20‐690363‐DIAN</funding_grant_id><funding_grant_id>P50 AG005681</funding_grant_id><funding_grant_id>P30 AG066519</funding_grant_id><funding_grant_id>P30 AG062715</funding_grant_id><funding_grant_id>U24 AG021886</funding_grant_id><funding_grant_id>U01 AG051412</funding_grant_id><funding_grant_id>R01 AG044546</funding_grant_id><funding_grant_id>RF1AG074007</funding_grant_id><funding_grant_id>P30 AG066444</funding_grant_id><funding_grant_id>R01 AG064877</funding_grant_id><funding_grant_id>U01 AG058922</funding_grant_id><funding_grant_id>R01 AG064614</funding_grant_id><funding_grant_id>P50 AG008702</funding_grant_id><funding_grant_id>LI‐W81XWH2010849</funding_grant_id><funding_grant_id>UL1 TR001873</funding_grant_id><funding_grant_id>UL1 TR002345</funding_grant_id><funding_grant_id>P30 AG062421</funding_grant_id><funding_grant_id>RF1 AG074007</funding_grant_id><funding_grant_id>UL1 TR001414</funding_grant_id><funding_grant_id>RF1AG053303</funding_grant_id><funding_grant_id>U19 AG068054</funding_grant_id><funding_grant_id>P50 HD105353</funding_grant_id><funding_grant_id>P50 AG005133</funding_grant_id><funding_grant_id>RF1 AG058501</funding_grant_id><funding_grant_id>U19 AG032438</funding_grant_id><funding_grant_id>UL1 TR001857</funding_grant_id><funding_grant_id>RF1 AG053303</funding_grant_id><funding_grant_id>U01 AG051406</funding_grant_id><funding_grant_id>SG-20-690363-DIAN</funding_grant_id><funding_grant_id>P01AG003991</funding_grant_id><funding_grant_id>U54 HD090256</funding_grant_id><funding_grant_id>U01 AG024904</funding_grant_id><funding_grant_id>P01 AG026276</funding_grant_id><funding_grant_id>P01 AG003991</funding_grant_id><pubmed_authors>Dominantly Inherited Alzheimer Network (DIAN), the Alzheimer's Disease Neuroimaging Initiative (ADNI)</pubmed_authors><pubmed_authors>Xicota L</pubmed_authors><pubmed_authors>Chhatwal JP</pubmed_authors><pubmed_authors>Mapstone M</pubmed_authors><pubmed_authors>Hassenstab J</pubmed_authors><pubmed_authors>Feingold E</pubmed_authors><pubmed_authors>Hom CL</pubmed_authors><pubmed_authors>Ances BM</pubmed_authors><pubmed_authors>Fernandez MV</pubmed_authors><pubmed_authors>Zaman SH</pubmed_authors><pubmed_authors>Cruchaga C</pubmed_authors><pubmed_authors>Gorijala P</pubmed_authors><pubmed_authors>Hartley SL</pubmed_authors><pubmed_authors>Kamboh MI</pubmed_authors><pubmed_authors>Fan KH</pubmed_authors><pubmed_authors>Surace EI</pubmed_authors><pubmed_authors>Aslam MM</pubmed_authors><pubmed_authors>NIA-LOAD family study, for the Alzheimer's Biomarkers Consortium-Down Syndrome (ABC-DS) Investigators</pubmed_authors><pubmed_authors>Dang LT</pubmed_authors><pubmed_authors>Perrin RJ</pubmed_authors><pubmed_authors>Sung YJ</pubmed_authors><pubmed_authors>Lee JH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.</name><description>&lt;h4>Introduction&lt;/h4>This study aimed to investigate the influence of the overall Alzheimer's disease (AD) genetic architecture on Down syndrome (DS) status, cognitive measures, and cerebrospinal fluid (CSF) biomarkers.&lt;h4>Methods&lt;/h4>AD polygenic risk scores (PRS) were tested for association with DS-related traits.&lt;h4>Results&lt;/h4>The AD risk PRS was associated with disease status in several cohorts of sporadic late- and early-onset and familial late-onset AD, but not in familial early-onset AD or DS. On the other hand, lower DS Mental Status Examination memory scores were associated with higher PRS, independent of intellectual disability and APOE (PRS including APOE, PRS&lt;sub>APOE&lt;/sub> , p = 2.84 × 10&lt;sup>-4&lt;/sup> ; PRS excluding APOE, PRS&lt;sub>nonAPOE&lt;/sub> , p = 1.60 × 10&lt;sup>-2&lt;/sup> ). PRS&lt;sub>APOE&lt;/sub> exhibited significant associations with Aβ42, tTau, pTau, and Aβ42/40 ratio in DS.&lt;h4>Discussion&lt;/h4>These data indicate that the AD genetic architecture influences cognitive and CSF phenotypes in DS adults, supporting common pathways that influence memory decline in both traits.&lt;h4>Highlights&lt;/h4>Examination of the polygenic risk of AD in DS presented here is the first of its kind. AD PRS influences memory aspects in DS individuals, independently of APOE genotype. These results point to an overlap between the genes and pathways that leads to AD and those that influence dementia and memory decline in the DS population. APOE ε4 is linked to DS cognitive decline, expanding cognitive insights in adults.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-08-12T03:04:38.886Z</modification><creation>2025-08-12T03:04:38.886Z</creation></dates><accession>S-EPMC10916941</accession><cross_references><pubmed>37855447</pubmed><doi>10.1002/alz.13506</doi></cross_references></HashMap>